167 related articles for article (PubMed ID: 22382554)
21. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys.
Xiao JJ; Krzyzanski W; Wang YM; Li H; Rose MJ; Ma M; Wu Y; Hinkle B; Perez-Ruixo JJ
AAPS J; 2010 Dec; 12(4):646-57. PubMed ID: 20737261
[TBL] [Abstract][Full Text] [Related]
23. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and biodistribution of a human monoclonal antibody to oxidized LDL in cynomolgus monkey using PET imaging.
Kamath AV; Williams SP; Bullens S; Cowan KJ; Stenberg Y; Cherry SR; Rendig S; Kukis DL; Griesemer C; Damico-Beyer LA; Bunting S
PLoS One; 2012; 7(9):e45116. PubMed ID: 23028793
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
[TBL] [Abstract][Full Text] [Related]
26. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
[TBL] [Abstract][Full Text] [Related]
27. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
Nnane IP; Xu Z; Zhou H; Davis HM
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):219-25. PubMed ID: 25683750
[TBL] [Abstract][Full Text] [Related]
28. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and Ascaris-challenged cynomolgus monkeys.
Vugmeyster Y; Tian X; Szklut P; Kasaian M; Xu X
Pharm Res; 2009 Feb; 26(2):306-15. PubMed ID: 18975059
[TBL] [Abstract][Full Text] [Related]
30. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A.
Gupta P; Kamath AV; Park S; Chiu H; Lutman J; Maia M; Tan MW; Xu M; Swem L; Deng R
MAbs; 2016 Jul; 8(5):991-7. PubMed ID: 27031797
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys.
Gu JM; Zhao XY; Schwarz T; Schuhmacher J; Baumann A; Ho E; Subramanyan B; Tran K; Myles T; Patel C; Koellnberger M
AAPS J; 2017 Jul; 19(4):1186-1195. PubMed ID: 28516358
[TBL] [Abstract][Full Text] [Related]
32. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
[TBL] [Abstract][Full Text] [Related]
33. Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration.
Lu Y; Xiang H; Liu P; Tong RR; Watts RJ; Koch AW; Sandoval WN; Damico LA; Wong WL; Meng YG
MAbs; 2009; 1(4):364-9. PubMed ID: 20068394
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.
Gibiansky L; Sutjandra L; Doshi S; Zheng J; Sohn W; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
Clin Pharmacokinet; 2012 Apr; 51(4):247-60. PubMed ID: 22420579
[TBL] [Abstract][Full Text] [Related]
35. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312).
Pawaskar D; Chen X; Glassman F; May F; Roberts A; Biondo M; McKenzie A; Nolte MW; Jusko WJ; Tortorici M
Clin Transl Sci; 2022 Mar; 15(3):709-720. PubMed ID: 34811931
[TBL] [Abstract][Full Text] [Related]
37. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.
Xiang H; Bender BC; Reyes AE; Merchant M; Jumbe NL; Romero M; Davancaze T; Nijem I; Mai E; Young J; Peterson A; Damico-Beyer LA
Clin Cancer Res; 2013 Sep; 19(18):5068-78. PubMed ID: 23894056
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
[TBL] [Abstract][Full Text] [Related]
39. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
[TBL] [Abstract][Full Text] [Related]
40. Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2.
Lee WS; Shim SR; Lee SY; Yoo JS; Cho SK
Drug Des Devel Ther; 2018; 12():495-504. PubMed ID: 29563774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
